Breast cancer assessment tools and optimizing adjuvant therapy

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Systemic adjuvant therapy selection for early-stage breast cancer presents ongoing challenges.
• Current prognostic and predictive tools, such as Adjuvant! Online, St Gallen Consensus, Oncotype DX, and MammaPrint, aid decision-making but have limitations.
• These limitations include dependence on accurate clinicopathological measurements and the oversight of tumor biological heterogeneity by multigene assays.

Purpose of the Study:

• To review the limitations of current adjuvant assessment tools in early-stage breast cancer.
• To emphasize the need for biologically driven treatment strategies.
• To explore future directions in personalized adjuvant therapy for breast cancer.

Main Methods:

• Review of existing adjuvant assessment tools for early-stage breast cancer.
• Analysis of the limitations of clinicopathological and multigene-based prognostic/predictive tools.
• Discussion of the biological heterogeneity of breast tumors and its implications for treatment.

Main Results:

• Existing adjuvant assessment tools have significant limitations, particularly for intermediate-risk patients.
• Multigene assays, while objective, do not fully capture tumor biological complexity.
• Current tools often fail to address the diverse nature of breast cancer biology.

Conclusions:

• Adjuvant therapy decisions for early-stage breast cancer require careful consideration of tool limitations.
• Future breast cancer management must be biologically driven, moving beyond broad molecular subgroups.
• Identifying predictive biomarkers for chemotherapy sensitivity will enable targeted use of agents like anthracyclines and taxanes, guided by drug targets and signaling pathways.